ArticleThe Lancet. Public health2022
Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study.
Article in The Lancet. Public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Economic Value of Non-pharmaceutical Interventions for Influenza and COVID-19: A Systematic Review.Applied health economics and health policy · 2026Pooled it
- Masks and respirators for prevention of respiratory infections: a state of the science review.Clinical microbiology reviews · 2024Pooled it
- Economic evaluation of COVID-19 vaccination: A systematic review.Journal of global health · 2023Pooled it
- Adherence to mask wearing and social distancing and use of lateral flow tests during the COVID19 pandemic in England and Wales based on the virus watch community cohort study.Discover public health · 2026Article
- Mask Usage in Healthcare Settings: Is It the Right Time for Easing Restrictions? A Narrative Review.Iranian journal of public health · 2025Review
- Optimal pandemic control strategies and cost-effectiveness of COVID-19 non-pharmaceutical interventions in the United States.BMC global and public health · 2025Article
- SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.International journal of molecular sciences · 2025Review
- Factors influencing mask-wearing behavior in the context of COVID-19 severity risks in the post-COVID-19 era: a Japanese Nationwide Epidemiological Survey in 2023.Environmental health and preventive medicine · 2025Article
- The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review.Cost effectiveness and resource allocation : C/E · 2024Article
- A Deep Learning-Enhanced Compartmental Model and Its Application in Modeling Omicron in China.Bioengineering (Basel, Switzerland) · 2024Article
- Modeling Nursing Home Harms From COVID-19 Staff Furlough Policies.JAMA network open · 2024Article
- Please wear a mask: a systematic case for mask wearing mandates.Journal of medical ethics · 2024Article
- Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes.Infection control and hospital epidemiology · 2024Article
- How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its Value.Journal of the American Medical Directors Association · 2024Article
- Effects of no mask, a surgical mask and a fabric buff on peripheral oxygenation saturation during moderate intensity exercise: a randomised cross-over study.Journal of thoracic disease · 2024Article
- The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study.EClinicalMedicine · 2024Article
- Cost-effectiveness of mask mandates on subways to prevent SARS-CoV-2 transmission in the United States.PloS one · 2024Article
- Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA.Applied health economics and health policy · 2024Article
- Airborne SARS-CoV-2 is more frequently detected in environments related to children and elderly but likely non-infectious, Norway, 2022.Virology journal · 2023Article
- Wearing masks as a protective measure for children against traffic-related air pollution: A comparison of perceptions between school children and their caregivers in Ho Chi Minh City, Vietnam.Tropical medicine & international health : TM & IH · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFace mask wearing has been an important part of the response to the COVID-19 pandemic. As vaccination coverage progresses in countries, relaxation of such practices is increasing. Subsequent COVID-19 surges have raised the questions of whether face masks should be encouraged or required and for how long. Here, we aim to assess the value of maintaining face masks use indoors according to different COVID-19 vaccination coverage levels in the USA.
methodsIn this computational simulation-model study, we developed and used a Monte Carlo simulation model representing the US population and SARS-CoV-2 spread. Simulation experiments compared what would happen if face masks were used versus not used until given final vaccination coverages were achieved. Different scenarios varied the target vaccination coverage (70-90%), the date these coverages were achieved (Jan 1, 2022, to July 1, 2022), and the date the population discontinued wearing face masks.
findingsSimulation experiments revealed that maintaining face mask use (at the coverage seen in the USA from March, 2020, to July, 2020) until target vaccination coverages were achieved was cost-effective and in many cases cost saving from both the societal and third-party payer perspectives across nearly all scenarios explored. Face mask use was estimated to be cost-effective and usually cost saving when the cost of face masks per person per day was ≤US$1·25. In all scenarios, it was estimated to be cost-effective to maintain face mask use for about 2-10 weeks beyond the date that target vaccination coverage (70-90%) was achieved, with this added duration being longer when the target coverage was achieved during winter versus summer. Factors that might increase the transmissibility of the virus (eg, emergence of the delta [B.1.617.2] and omicron [B.1.1.529] variants), or decrease vaccine effectiveness (eg, waning immunity or escape variants), or increase social interactions among certain segments of the population, only increased the cost savings or cost-effectiveness provided by maintaining face mask use.
interpretationOur study provides strong support for maintaining face mask use until and a short time after achieving various final vaccination coverage levels, given that maintaining face mask use can be not just cost-effective, but even cost saving. The emergence of the omicron variant and the prospect of future variants that might be more transmissible and reduce vaccine effectiveness only increases the value of face masks.
fundingThe Agency for Healthcare Research and Quality, the National Institute of General Medical Sciences, the National Science Foundation, the National Center for Advancing Translational Sciences, and the City University of New York.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.